This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group, Critical Reviews in Oncology/Hematology, October 2023, Elsevier,
DOI: 10.1016/j.critrevonc.2023.104108.
You can read the full text:
The following have contributed to this page
